Component
Human MCI cognitive/functional outcomes during lithium trials
Context-specific entity; species, compartment and exposure are stated on each claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
None of six coprimary outcomes met the prespecified significance threshold in the 2026 low-dose lithium trial.
Experimental context and source evidence
- evidence_access
- Primary full text
- experimental_model
- NCT03185208; 83 randomized, 80 started; two years; prespecified P<.01.
- limitations
- Verbal-recall difference P=.05 and exploratory amyloid subgroups are not positive primary results.
- nutrient_topic
- Lithium collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Lithium
- plain_language
- The newer pilot did not confirm its primary efficacy hypotheses.
- primary_references
- Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/41770546/ · DOI 10.1001/jamaneurol.2026.0072
Lithium: metal-sensitive enzymes, transport and cross-nutrient mechanisms (2026-09-19) · lines 536–542
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · NCT03185208; 83 randomized, 80 started; two years; prespecified P<.01. · source_derived_draft · unverified_draft
## lithium-mci-2026-primary-null The newer pilot did not confirm its primary efficacy hypotheses. None of six coprimary outcomes met the prespecified significance threshold in the 2026 low-dose lithium trial. Model: NCT03185208; 83 randomized, 80 started; two years; prespecified P<.01. Limitations: Verbal-recall difference P=.05 and exploratory amyloid subgroups are not positive primary results. Evidence access: Primary full text Low-Dose Lithium for Mild Cognitive Impairment: A Pilot Randomized Clinical Trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/41770546/ · DOI 10.1001/jamaneurol.2026.0072
Complete structured claim and evidenceA 61-person trial reported cognitive/functional stability with lithium versus decline with placebo over two years.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- Amnestic MCI; lithium carbonate target 0.25–0.5 mEq/L; NCT01055392.
- limitations
- Single trial; population, exposure, endpoints and follow-up differ from later studies.
- nutrient_topic
- Lithium collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Lithium
- plain_language
- One small human trial reported a favorable result.
- primary_references
- Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. · 2019 · https://pubmed.ncbi.nlm.nih.gov/30947755/ · DOI 10.1192/bjp.2019.76
Lithium: metal-sensitive enzymes, transport and cross-nutrient mechanisms (2026-09-19) · lines 528–534
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Amnestic MCI; lithium carbonate target 0.25–0.5 mEq/L; NCT01055392. · source_derived_draft · unverified_draft
## lithium-mci-positive One small human trial reported a favorable result. A 61-person trial reported cognitive/functional stability with lithium versus decline with placebo over two years. Model: Amnestic MCI; lithium carbonate target 0.25–0.5 mEq/L; NCT01055392. Limitations: Single trial; population, exposure, endpoints and follow-up differ from later studies. Evidence access: Primary abstract Clinical and biological effects of long-term lithium treatment in older adults with amnestic mild cognitive impairment: randomised clinical trial. · 2019 · https://pubmed.ncbi.nlm.nih.gov/30947755/ · DOI 10.1192/bjp.2019.76
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.